MPI Research Acquires Jasper Clinical Research & Development
Addition of clinical trials company expands MPI Research capabilities to include human Phase I testing.
MPI Research announced it has acquired the assets of Kalamazoo, Mich.-based Jasper Clinical Research & Development, Inc., a clinical research organization that provides early-stage human clinical testing of new drugs.
The acquisition includes the Jasper Clinic, a 50-bed clinical trial unit that provides early-stage study services, including pharmacokinetic and pharmacodynamics, drug interaction and methodology studies, and expertise in integrating pharmacogenetics and biomarkers into studies. The three-story, 25,000-square-foot clinic is located on the downtown Kalamazoo campus of Bronson Hospital, and is physically connected to Bronson’s Level 1 trauma center.
The acquisition marks the second service expansion by MPI Research in the past year. In May 2014, the company, along with partners inviCRO and 3D Imaging, opened the Translational Imaging Center, which includes a cyclotron, specialized services, and is connected to a vivarium. This facility and the expertise associated with it will permit drug radiolabeling and in-depth distribution studies across a wide variety of animal and human models, MPI reports in a statement.
Source: MPI Research
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
